Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) - Equities researchers at HC Wainwright increased their Q3 2024 EPS estimates for Sana Biotechnology in a research report issued to clients and investors on Tuesday, November 5th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($0.25) for the quarter, up from their prior estimate of ($0.30). HC Wainwright currently has a "Buy" rating and a $8.00 target price on the stock. The consensus estimate for Sana Biotechnology's current full-year earnings is ($1.13) per share. HC Wainwright also issued estimates for Sana Biotechnology's Q4 2024 earnings at ($0.19) EPS, FY2024 earnings at ($1.09) EPS, FY2025 earnings at ($0.77) EPS, FY2026 earnings at ($0.75) EPS, FY2027 earnings at ($0.72) EPS and FY2028 earnings at ($0.61) EPS.
Several other equities research analysts have also issued reports on the company. JMP Securities lowered Sana Biotechnology from an "outperform" rating to a "market perform" rating in a research note on Tuesday. Citigroup raised their price target on Sana Biotechnology from $8.00 to $15.00 and gave the stock a "buy" rating in a research note on Friday, August 9th.
View Our Latest Research Report on Sana Biotechnology
Sana Biotechnology Stock Performance
Sana Biotechnology stock traded down $0.31 during mid-day trading on Thursday, hitting $3.10. 2,715,419 shares of the company traded hands, compared to its average volume of 2,155,079. Sana Biotechnology has a one year low of $2.85 and a one year high of $12.00. The stock has a market cap of $689.64 million, a price-to-earnings ratio of -2.72 and a beta of 1.44. The stock has a fifty day moving average price of $4.33 and a 200-day moving average price of $5.86.
Sana Biotechnology (NASDAQ:SANA - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.04).
Insiders Place Their Bets
In other news, Director Richard Mulligan sold 150,000 shares of the business's stock in a transaction on Tuesday, September 24th. The shares were sold at an average price of $4.08, for a total transaction of $612,000.00. Following the sale, the director now owns 2,848,121 shares in the company, valued at approximately $11,620,333.68. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 31.10% of the stock is owned by corporate insiders.
Institutional Trading of Sana Biotechnology
Several hedge funds and other institutional investors have recently made changes to their positions in SANA. Vanguard Group Inc. increased its stake in Sana Biotechnology by 24.1% during the 1st quarter. Vanguard Group Inc. now owns 12,155,173 shares of the company's stock valued at $121,552,000 after purchasing an additional 2,358,089 shares in the last quarter. Capital World Investors raised its holdings in Sana Biotechnology by 255.8% in the 1st quarter. Capital World Investors now owns 5,449,035 shares of the company's stock worth $54,490,000 after acquiring an additional 3,917,728 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Sana Biotechnology by 2.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,695,459 shares of the company's stock valued at $36,956,000 after acquiring an additional 101,434 shares in the last quarter. Baker BROS. Advisors LP boosted its stake in Sana Biotechnology by 19.0% during the 1st quarter. Baker BROS. Advisors LP now owns 2,380,949 shares of the company's stock valued at $23,809,000 after purchasing an additional 380,949 shares during the last quarter. Finally, Integral Health Asset Management LLC increased its holdings in shares of Sana Biotechnology by 22.4% in the 2nd quarter. Integral Health Asset Management LLC now owns 1,200,000 shares of the company's stock worth $6,552,000 after purchasing an additional 220,000 shares in the last quarter. Hedge funds and other institutional investors own 88.23% of the company's stock.
Sana Biotechnology Company Profile
(
Get Free Report)
Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.
Featured Articles
Before you consider Sana Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sana Biotechnology wasn't on the list.
While Sana Biotechnology currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
